Belite Bio

Update in progress

BLTE (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Belite Bio, Inc. is a San Diego-based clinical-stage biopharmaceutical company developing novel therapies for retinal degenerative diseases with unmet medical needs in the United States. Its lead candidate, Tinlarebant (LBS-008), is an oral therapy in phase 3 for early intervention to preserve retinal health in Stargardt disease type 1 and geographic atrophy. LBS-009 is a preclinical oral anti-RBP4 candidate targeting liver disease, NAFLD/NASH, type 2 diabetes, and gout. Founded in 2016, it is a subsidiary of Lin Bioscience International Ltd.

Company score

Sentiment: 0.41; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.29; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive